Physician profile
John D Mitchell
NPI 1952442253
$1,700.64
in general payments reported to CMS, 2019-2025
20 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $145 · 2021: $88.84 · 2022: $404 · 2023: $218 · 2024: $327 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.47 | 2022-2024 | |
| Alcon Vision LLC | $198.51 | 2021-2025 | Clareon, Argos, Lensx |
| Staar Surgical Company | $146.92 | 2019 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $121.67 | 2020-2024 | |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Allergan, INC. | $77.02 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $72.01 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $60.63 | 2019-2021 | |
| Dompe US, INC. | $60.12 | 2022-2024 | Oxervate |
| Integra Lifesciences Corporation | $52.00 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Thea Pharma INC. | $47.58 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $40.72 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Glaukos Corporation | $32.49 | 2025 | Istent Infinite |
| Rxsight INC | $26.87 | 2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.51 | 2021 | |
| Apellis Pharmaceuticals, INC. | $24.10 | 2025 | Syfovre |
| Harrow Eye, LLC | $23.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.01 | 2023 | |
| Sight Sciences, INC. | $16.74 | 2025 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.